CYP19A1 and breast cancer: Early data from the ABCSG-18 study, a phase III trial of 3425 postmenopausal patients with early hormone receptor positive BC receiving aromatase inhibitors treatment with or without denosumab (60 mg every six months), showed a reduction in the risk of recurrence of approximately 18% (HR 0.816 (95% CI 0.66–1.00), p = 0.051) [105].